Irritable bowel syndrome: A practical approach

Nutrition in Clinical Practice

Volumn 23, Issue 3, 2008, Pages 263-267

  Clark, Christian ^a   Delegge, Mark ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE   (United States)

Author keywords

Colon; Constipation; Diarrhea; Gastroenterology; Small intestine; Visceral afferents

Indexed keywords

ALOSETRON; BELLADONNA ALKALOID; BISACODYL; CORTICOTROPIN RELEASING FACTOR; DICYCLOVERINE; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; ISPAGULA; LACTULOSE; MACROGOL; MAGNESIUM SALT; METHYLCELLULOSE; NORTRIPTYLINE; PHOSPHATE; POLYCARBOPHIL; SENNA EXTRACT; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SORBITOL; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; ADRENERGIC RECEPTOR AFFECTING AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; BEDTIME DOSAGE; BLOATING; CASE REPORT; CHOLECYSTECTOMY; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DEPRESSION; DIARRHEA; DIET RESTRICTION; DIETARY INTAKE; DRUG DEPENDENCE; DYSPEPSIA; ENDOSCOPY; ENTERITIS; FEMALE; GASTROINTESTINAL MUCOSA; GENETIC ASSOCIATION; HUMAN; HYPERALGESIA; HYPERSENSITIVITY; INTESTINE FLORA; INTESTINE MOTILITY; IRRITABLE COLON; LOW FAT DIET; MUCOSA INFLAMMATION; NAUSEA; NEUROSIS; PATHOPHYSIOLOGY; PHOBIA; PSYCHOTHERAPY; RELAXATION TRAINING; REVIEW; SEXUAL ABUSE; SIDE EFFECT; SOMATIZATION; TACHYPHYLAXIS; UNSPECIFIED SIDE EFFECT; VOMITING; AUTONOMIC NERVOUS SYSTEM; DIFFERENTIAL DIAGNOSIS; ENVIRONMENT; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INNERVATION; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PREVALENCE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AUTONOMIC NERVOUS SYSTEM; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; ENVIRONMENT; FEMALE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IRRITABLE BOWEL SYNDROME; NORTRIPTYLINE; PITUITARY-ADRENAL SYSTEM; PREVALENCE;

EID: 53449087410     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0884533608318107     Document Type: Review

References (51)

1. Shih YT, Barghout V., Sandler RS Resource utilization associated with irritable bowel syndrome in the United States: 1987-1997. Dig Dis Sci. 2002 ; 47: 1705-1715. (Pubitemid 34833198)
2. Drossman DA, Andruzzi E., Temple RD U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci. 1993, 38: 1569-1580. (Pubitemid 23271409)
3. Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001 ; 121: 799-804. (Pubitemid 32959390)
4. Latimer P., Sarna S., Campbell D., Latimer M., Waterfall W., Daniel EE Colonic motor and myoelectrical activity: a comparative study of normal subjects, psychoneurotic patients, and patients with irritable bowel syndrome. Gastroenterology. 1981 ; 80: 893-901. (Pubitemid 11113027)
5. Jepsen JM, Skoubo-Kristensen E., Elsborg L. Rectosigmoid motility response to sham feeding in irritable bowel syndrome: evidence of a cephalic phase. Scand J Gastroenterol. 1989 ; 24: 53-56. (Pubitemid 19071839)
6. Cann PA, Read NW, Brown C., Hobson N., Holdsworth CD Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. 1983 ; 24: 405-411.
7. Kellow JE, Eckersley GM, Jones M. Enteric and central contributions to intestinal dysmotility in irritable bowel syndrome. Dig Dis Sci. 1992 ; 37: 168-174.
8. Rothstein RD Irritable bowel syndrome. Med Clin North Am. 2000 ; 84: 1247-1257.
9. Coulie B., Camilleri M., Gupta V. Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig Dis Sci. 2002 ; 2: 895-904.
10. Lawal A., Kern M., Sidhu H., Hoffman C., Shaker R. Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology. 2006 ; 130: 26-33. (Pubitemid 43049832)
11. Whitehead, WE, Holtkotter, B., Enck P., et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology. 1990 ; 98: 1187-1192. (Pubitemid 20143101)
12. Cook IJ, van Eeden A., Collins SM Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology. 1987 ; 93: 727-733. (Pubitemid 17155997)
13. Munakata J., Naliboff B., Harraf F., et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology. 1997 ; 112: 55-63. (Pubitemid 27008986)
14. Trimble KC, Farouk R., Pryde A. Heightened visceral sensation in functional gastrointestinal disease is not site-specific: evidence for a generalized disorder of gut sensitivity. Dig Dis Sci. 1995 ; 40: 1607-1613.
15. Chun AB, Desautels S., Slivka A. Visceral algesia in irritable bowel syndrome, fibromyalgia, and sphincter of oddi dysfunction, type III. Dig Dis Sci. 1999 ; 44: 631-638.
16. Bouin M., Lupien F., Riberdy M., Boivin M., Plourde V., Poitras M. Intolerance to visceral distention in functional dyspepsia or irritable bowel syndrome: an organ specific defect or a pain intestinal dysregulation. Neurogastroenterol Motil. 2004 ; 16: 311-314. (Pubitemid 38869654)
17. Silverman DH, Munakata J., Ennes H., Mandelkern ML, Hoh CK, Mayer EA Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology. 1997 ; 112: 64-72. (Pubitemid 27008987)
18. Mertz H., Morgan V., Tanner G., et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000 ; 118: 842-848. (Pubitemid 30243747)
19. Sidu H., Kern M., Shaker R. Absence of increasing cortical fMRI activity volume in response to increasing visceral stimulation in IBS patients. Am J Physiol Gastrointest Liver Physiol. 2004 ; 287: G425 - G435.
20. Bueno L., Fioramonti J., Garcia-Villar R. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications, III: Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol. 2000 ; 278: G670 - G679.
21. Gershon MD Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther. 1999 ; 13: 15-30. (Pubitemid 29219277)
22. Chadwick VS, Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002 ; 122: 1778-1783. (Pubitemid 34651421)
23. Tornblom H., Lindberg G., Nyberg B., Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002 ; 123: 1972-1979. (Pubitemid 35408321)
24. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004 ; 126: 693-702. (Pubitemid 38298317)
25. Neal KR, Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997 ; 314: 779-782. (Pubitemid 27117047)
26. Barbara G., Wang B., Stanghellini V., et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007 ; 132: 26-37. (Pubitemid 46108761)
27. Marshall JK, Thabane M., Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol. 2007 ; 5: 457-460. (Pubitemid 46575359)
28. Halvorson HA, Schlett CD, Riddle MS Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol. 2006 ; 101: 1894-1899.
29. Marshall KA, Thabane M., Garg AX, et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006 ; 131: 445-450.
30. Everest PH, Goossens H., Butzler JP, et al. Differentiated Caco-2 cells as a model for enteric invasion by Campylobacter jejuni and E coli. J Med Microbiol. 1992 ; 37: 319-325.
31. Swain, MG, Blennerhassett PA, Collins SM Impaired sympathetic nerve function in the inflamed rat intestine. Gastroenterology. 1991 ; 100: 675-682.
32. Kassinen A., Krogius-Kurikka L., Makivuokko H., et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007 ; 133: 24-33. (Pubitemid 47031125)
33. Swidsinki A., Khilkin M., Ortner M. Alteration of bacterial concentrations in colonic biopsies from patients with irritable bowel syndrome [abstract]. Gastroenterology. 1999 ; 116: A1.
34. Whitehead WE, Bosmajian L., Zonderman AB, Costa PT Jr, Schuster MM Symptoms of psychological distress associated with irritable bowel syndrome: comparisons of community and medical clinic samples. Gastroenterology. 1988 ; 95: 709-714. (Pubitemid 18207432)
35. Drossman DA, Leserman J., Nachman G., Pezzotti P., Corazziari E. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med. 1990 ; 113: 828-833.
36. Talley NJ, Boyce PM, Jones M. Is the association between irritable bowel syndrome and abuse explained by neuroticism? A population based study. Gut. 1998 ; 42: 47-53. (Pubitemid 28228387)
37. Horwoitz BJ, Fisher RS The irritable bowel syndrome. N Engl J Med. 2001 ; 344: 1846-1850.
38. Keck ME, Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides. 2001 ; 22: 835-844. (Pubitemid 32397736)
39. Sagami Y., Shimada Y., Tayama J., et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut. 2004 ; 53: 958-964. (Pubitemid 38824152)
40. Camilleri M., Atansova E., Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002 ; 123: 425-432. (Pubitemid 34827186)
41. Attar A., Lemann M., Ferguson A., et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999 ; 44: 226-230. (Pubitemid 29119366)
42. Jailwala J., Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000 ; 133: 136-147. (Pubitemid 30490414)
43. Su X., Gebhart GF Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain. 1998 ; 76: 105-114. (Pubitemid 28304946)
44. Botney M., Fields HL Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol. 1983 ; 13: 160-164. (Pubitemid 13188210)
45. McQuay HJ, Moore RA Antidepressants and chronic pain. BMJ. 1997 ; 314: 763-764. (Pubitemid 27117040)
46. Pimentel M., Chow EJ, Lin HC Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000 ; 95: 3503-3506.
47. Serra J., Salvioli B., Azpiroz F., Malagelada JR Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology. 2002 ; 123: 700-706. (Pubitemid 34977075)
48. Talley NJ, Owen, BK, Boyce P., Paterson K. Psychological treatments of irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol. 1996 ; 91: 277-283.
49. Camilleri M., Mayer EA, Drossman DA, et al. Improvement of pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 ; 13: 1149-1159. (Pubitemid 29445893)
50. Guslandi M. Probiotic agents in the treatment of irritable bowel syndrome. J Int Med Res. 2007 ; 35: 583-589. (Pubitemid 47570478)
51. Muller-Lissner SA, Fumagalli I., Bardham KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001 ; 15: 1655-1666. (Pubitemid 32912410)